Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 19, Issue SUPPL. 2, 2008, Pages

  Casali, P G ^a,f   Jost, L ^b,f   Reichardt, P ^c,f   Schlemmer, M ^d,f   Blay, J Y ^e,f  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b KANTONSSPITAL   (Switzerland)

^c HELIOS Klinikum Bad Saarow   (Germany)

^d Medical Clinic III   (Germany)

^e UNIVERSITÉ LYON 1   (France)

^f ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMATINIB; SUNITINIB;

ARTICLE; CANCER INCIDENCE; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; EXCISION; FOLLOW UP; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL STROMAL TUMOR; HISTOPATHOLOGY; HUMAN; LAPAROSCOPY; MUTATIONAL ANALYSIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; INCIDENCE; PATHOLOGY;

FOLLOW-UP STUDIES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INCIDENCE; NEOPLASM STAGING;

EID: 45149093253     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn080     Document Type: Article

References (15)

1. Benjamin RS, Choi H, Macapinlac HA et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25: 1760-1764.
2. Blanke CD, Rankin C, Demetri GD et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 2008; 26: 626-632.
3. Blay JY, Le Cesne A, Ray-Coquard I et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: The French Sarcoma Group. J Clin Oncol 2007; 25: 1107-1113.
4. Debiec-Rychter M, Sciot R, Le Cesne A et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42: 1093-1103.
5. DeMatteo RP, Gold JS, Saran L et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer 2008; 112: 608-615.
6. DeMatteo RK, Owzar KR, Maki R et al. Adjuvant imatinib mesylate increases recurrence free survival (RFS) in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American intergroup phase III trial ACOSOG Z9001. ASCO Annual Meetings Proceedings Part I. J Clin Oncol 2007; 25 (18 Suppl): 10079.
7. Demetri GD, van Oosterom AT, Garrett CR et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 2006; 368: 1329-1338.
8. Demetri GD, von Mehren M, Blanke CD et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
9. Fletcher CDM, Berman JJ, Corless C et al. Diagnosis of gastrointestinal stromal tumors: A consensus approach. Human Pathol 2002; 33: 459-465.
10. Miettinen M, Lasota J. Gastrointestinal stromal tumors: Review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006; 130: 1466-1478.
11. Novitsky YW, Kercher KW, Sing RF, Heniford BT. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 2006; 243: 738-745.
12. Raut CP, Posner M, Desai J et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006; 24: 2325-2331.
13. Van Glabbeke M, Verveij J, Casali PG et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: A European Organization for Research and Treatment of Cancer - Italian Sarcoma Group - Australasian Gastrointestinal Trials Group study. J Clin Oncol 2005; 23: 5795-5804.
14. Verweij J, Casali PG, Zalcberg J et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatininb: Randomized trial. Lancet 2004; 364: 1127-1134.
15. Zalcberg JR, Verveij J, Casali PG et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 2005; 41: 1751-1757.